Physician profile
Nirav K Shah
NPI 1477505329
$13,948.19
in general payments reported to CMS, 2019-2025
27 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $1,023 · 2021: $3,427 · 2022: $4,404 · 2023: $2,327 · 2024: $898 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,281.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $4,012.70 | 2019-2022 | |
| Nevro Corp. | $2,379.49 | 2022-2024 | Senza |
| Orthofix Medical, INC. | $1,467.50 | 2020-2021 | |
| Electronic Waveform Lab, INC. | $1,039.41 | 2021-2024 | |
| Boston Scientific Corporation | $1,038.83 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Watchman Flx |
| Stryker Corporation | $767.17 | 2022-2024 | Prolift, Vitoss, Actishield |
| Globus Medical, INC. | $652.13 | 2025 | Senza |
| Glaxosmithkline, LLC. | $551.26 | 2019-2024 | Arexvy, Nucala, Trelegy Ellipta |
| Abbott Laboratories | $509.73 | 2019-2024 | Proclaim |
| Medtronic, INC. | $353.92 | 2021-2024 | Intellis Adaptivestim |
| Intrinsic Therapeutics | $196.39 | 2022-2025 | Barricaid Acd (Annular Closure Device) |
| Nuvasive, INC. | $194.35 | 2019-2020 | |
| Spinal Simplicity, LLC | $180.86 | 2022 | |
| Spacelabs Healthcare INC | $138.38 | 2021 | |
| Genzyme Corporation | $104.58 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $69.26 | 2021 | |
| Medtronic USA, INC. | $57.91 | 2019 | |
| Zimmer Biomet Holdings, INC. | $55.58 | 2019 | |
| Dilon Technologies, INC. | $49.67 | 2024 | Hemoblast Bellows |
| Abbvie INC. | $39.77 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $27.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.17 | 2025 | |
| Genentech USA, INC. | $14.87 | 2023 | Xolair |
| Mylan Specialty L.P. | $14.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.68 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.